Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Myricetin dispersion tablets for treating cardio-cerebral blood vessel diseases and preparation method thereof

A technology of dispersible tablets and myricetin, which is applied to cardiovascular system diseases, blood diseases, metabolic diseases, etc., can solve the problems of affecting the efficacy of tablets, reducing bioavailability, and affecting the absorption of main ingredients, so as to achieve good prevention and treatment effects , Improve the absorption rate in the body and improve the solubility of the main drug

Inactive Publication Date: 2010-01-06
广西中医学院
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the medicines or health foods made from myricetin extract produced abroad are mainly ordinary tablets, but because the water solubility and fat solubility of myricetin are quite poor, the absorption in the body is slow, and the bioavailability is very low, so it works after taking medicine. Not ideal enough, affecting the curative effect of existing tablets
There is also an attempt to make myricetin into dripping pills to improve its dissolution rate and absorption rate in the body; but this dosage form is not stable enough, and it is easy to produce aging phenomena such as drug crystallization and dissolution rate reduction after long-term placement, thereby affecting the composition of the main drug components. Absorption, making it less bioavailable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Myricetin dispersion tablets for treating cardio-cerebral blood vessel diseases and preparation method thereof
  • Myricetin dispersion tablets for treating cardio-cerebral blood vessel diseases and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Myricetin 100g

[0021] Cross-linked polyvinylpyrrolidone 13g (internal addition)

[0022] 4g (additional)

[0023] Polyvinylpyrrolidone 15g

[0024] Microcrystalline Cellulose 57g

[0025] α-Lactose 57g

[0026] Sodium Lauryl Sulfate 5g (additional)

[0027] Magnesium stearate 1.3g (additional)

[0028] Appropriate amount of essence (additional)

[0029]

[0030] A total of 1000 pieces

[0031] Weigh the drug and the excipients after passing through the 100-mesh sieve according to the prescription amount, fully mix the drug and the internally added excipients with the equal-volume incremental method, and grind. Add the prepared 10% polyvinylpyrrolidone aqueous solution, fully grind to make soft material. Pass the prepared soft material through a 50-mesh sieve to make wet granules, and then dry it in an oven at 60°C for 2 hours. After taking it out, pass it through a 50-mesh sieve for granul...

Embodiment 2

[0036] Myricetin 100g

[0037] ice flakes 2g

[0038] Cross-linked polyvinylpyrrolidone 12g (internal addition)

[0039] 4g (additional)

[0040] Polyvinylpyrrolidone 15g

[0041] Microcrystalline Cellulose 58g

[0042] Pregelatinized starch 57g

[0043] Sodium Lauryl Sulfate 4g (additional)

[0044] Magnesium stearate 1.2g (additional)

[0045] Appropriate amount of essence (additional)

[0046]

[0047] A total of 1000 pieces

[0048] Its preparation process and method are the same as in Example 1.

[0049] Each tablet of this product weighs about 250mg, contains myricetin 100mg / tablet, and borneol 2mg / tablet. The appearance is yellow-green, uniform in color, and all indicators are in line with the relevant regulations of the 2005 edition of the "Chinese Pharmacopoeia".

[0050] Usage and dosage: Take orally, 1-2 tablets each time, 3 times a day.

[0051] Storage: sealed, in a cool dry place.

Embodiment 3

[0053] Myricetin 200g

[0054] Polyvinylpyrrolidone 35g

[0055] Microcrystalline Cellulose 150g

[0056] 130g pregelatinized starch

[0057] Sodium Lauryl Sulfate 10g (additional)

[0058] Magnesium stearate 2.5g (additional)

[0059] Appropriate amount of essence (additional)

[0060]

[0061] A total of 1000 pieces

[0062] Its preparation process and method are the same as in Example 1.

[0063] Each tablet of this product weighs about 0.5g and contains 200mg myricetin per tablet. The appearance is yellow-green, uniform in color, and all indicators are in line with the relevant regulations of the 2005 edition of the "Chinese Pharmacopoeia".

[0064] Usage and dosage: Take orally, 1 tablet each time, 3 times a day.

[0065] Storage: sealed, in a cool dry place.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a myricetin dispersion tablet for curing angiocardiopathy and cerebrovascular disease. Its composition contains (by weight portion) 100-200 portions of myricetin or myricetin containing 2% of borneol, 10-35 portions of cross-linked polyvinylpyrrolidone, 40-150 portions of microcrystal cellulose, 40-80 portions of alpha-lactose or 50-150 portions of pregelled starch, 10-35 portions of polyvinylpyrrolidone, 1-10 portions of sodium lauryl sulfate and 1-5 portions of magnesium stearate. Said invention also provides the preparation method of said dispersion tablet.

Description

technical field [0001] The invention relates to a medicine for preventing and treating cardiovascular and cerebrovascular diseases, and also relates to a preparation method of the medicine for preventing and treating cardiovascular and cerebrovascular diseases. Background technique [0002] Cardiovascular and cerebrovascular diseases are diseases that seriously endanger human health. Platelet activating factor (platelet activating factor, PAF) is the strongest platelet aggregation activator and important inflammatory mediator known so far. It can act on a variety of cell receptors and produce a wide range of biological effects. PAF participates in many pathophysiological changes, and is closely related to the pathogenesis of many heart and cerebrovascular diseases such as ischemia-reperfusion, inflammatory response, atherosclerosis, etc.; antagonizing the effect of PAF is the current way to inhibit thrombosis and improve various blood circulation disorders. , an important w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61K31/045A61K9/20A61K47/38A61P3/06A61P7/02A61P9/10
Inventor 覃洁萍王乃平陈卫卫张炜谭建宁蔡毅冯旭
Owner 广西中医学院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com